Issue 106

Medical Psychedelic Technical Advisory Board

Crispin Blunt MP joins Psych Capital

Psych Capital Plc is pleased to announce the appointment of the Conservative Drug Policy Reform Group (CDPRG) representative, Crispin Blunt MP, to its Medical Psychedelic Technical Advisory Board.

Since Psych Capital’s IPO, the board has been reviewing the regulatory landscape and investment opportunities in the UK, Europe and further afield, including drug development and patient delivery pathways.

It has been actively working with the CDPRG as part of its existing advisory agreement with them.

The expertise of the CDPRG in identifying regulatory barriers and opportunities, patient need, healthcare delivery frameworks, and political landscapes, has been instrumental as Psych Capital assesses a number of opportunities for strategic deployment of capital, leveraging its position as the first listed psychedelic company in London.

PSILOCYBIN RESEARCH RESTRICTIONS

Awakn Life Sciences’ Professor David Nutt spoke with The Guardian on regulations restricting psychedelic research in the UK.

STUDY LINKS LOW SEROTONIN WITH DEPRESSION

An Imperial College London study found evidence to support the theory that depression is caused by a slump in serotonin transmission.

BUSINESS AND INVESTMENT

COMPASS Pathways reports Q3 2022 financial results.

Contextualising adverse effects of psychedelic medicine.

Potential of psychedelic healthcare’s efficacy being overstated.

Awakn partners with Nushama in New York.

Preparing for psychedelic therapies in Australia.

Safety concerns with tele-health and psychedelic medicine.

Microdosing LSD as a treatment for depression.

Biomind Phase II DMT data for treatment-resistant depression.

Clairvoyant starts Phase II psilocybin study for alcohol-use disorder.

Beckley Psytech doses patients with intravenous psilocin formulation.

On Thursday, 17 November, healthcare leaders will converge in London to accelerate innovation in psychedelic medicine.

The event coincides with the release of The Psychedelics as Medicine Report: Fourth Edition, the industry’s leading data and insights publication, and Jefferies 2022 London Healthcare Conference.

To register your interest, please visit the website.

Website